Alendronate sodium is a bisphosphonate used to treat Paget disease of bone (PDB). The approved dosage of 40 mg/day for 6 months is generally well tolerated, but esophageal irritation can occur if ...

Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

Alendronate (Fosamax) reduces fracture rates among women with osteoporosis, usually defined as bone mineral density T-scores lower than -2.5. However, the benefit of alendronate in women with ...